Allogene reports Q2 2023 net loss of $78.0M; cash extends into 2H 2025

Allogene Therapeutics, Inc.

2023-Q2 EPS reported -$1.21 revenue$96,000

Cash, equivalents, and investments $544.5M as of June 30, 2023; raised $87.9M via ATM in Q2.
Net loss $78.0M ($0.53/share) including $16.6M non-cash stock-based comp.
ALLO-501A Phase 2 ALPHA2 enrollment expected to complete 1H 2024; data readout by year-end 2024.
Long-term data from ALPHA/ALPHA2 trials showed complete response rates similar to approved autologous CAR T.
Cash runway now projected into 2H 2025; 2023 operating expense guidance ~$340M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Allogene Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 2, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-23-000074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.